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Edited by Varda RotterAbstract p63 is a member of the p53 family of proteins and
plays an important role in epithelial development and diﬀerenti-
ation. Although some p63 binding sites in the regulatory ele-
ments of epithelial genes have been identiﬁed, the optimal
DNA-binding sequence has not been ascertained for this tran-
scription factor. Here, we identify the preferred DNA-binding
site of p63 by performing in vitro DNA selection experiments.
Our analysis shows that the optimal p63 DNA-binding consensus
motif consists of a CA(T)TG core and an AT-rich 5 0 and 3 0
ﬂanking sequence. Gel shift and competition experiments demon-
strate that there are speciﬁc sequence requirements that confer
high DNA-binding aﬃnity for p63 and that signiﬁcant deviation
from the consensus sequences result in poor or no binding. This
pattern of DNA-binding is similar for both recombinant p63
and the endogenous protein present in keratinocyte nuclear ex-
tracts. Furthermore, we show that the consensus sequence is dis-
tinctly diﬀerent from that of p53, particularly in the ﬂanking
sequences. Identiﬁcation of the p63 consensus DNA-binding se-
quence will facilitate the validation of in vivo p63-responsive ele-
ments that mediate transcriptional regulation of a wide variety of
target genes.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Keratinocyte1. Introduction
p63 is a member of the p53 tumor suppressor gene family
that plays a crucial role in transcriptional regulation of a num-
ber of genes involved in developmental and cellular responses
[1]. In particular, p63 is involved in limb, skin and craniofacial
morphogenesis as evident by the dramatic phenotype of the
p63 null mice [2,3]. These animals exhibit profound defects
in the skin epidermis as well as abnormalities of limb, mam-
mary and prostate development. In addition, germ line muta-
tions of p63 in humans are associated with congenital
abnormalities characterized by abnormal limb development
and/or ectodermal dysplasia, phenotypes that are similar to
p63 null mice [4–6]. The physiological role of p63 in the epithe-
lial development and diﬀerentiation process is in agreement*Corresponding author. Fax: +1 716 829 2725.
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doi:10.1016/j.febslet.2006.07.004with high levels of expression of p63 in select epithelial cells
such as those present in the embryonic ectoderm and the basal
proliferating cells of many epithelial tissues such as skin, oral
epithelium, breast myoepithelium and prostate [4,7–9].
The p63 gene is complex and encodes for at least six unique
isoforms. Diﬀerential promoter usage produces two major pro-
tein isoforms that either contain or lack the N-terminal trans-
activation domain (TAp63 and DNp63, respectively). In
addition, diﬀerential mRNA splicing leads to generation of
three distinct isoforms (a, b and c), which diﬀer in their C-ter-
minal domains. This proclivity to generate multiple isoforms is
not restricted to p63 alone, but is also characteristic of p73, an-
other p53 family member. As recent studies indicate, this is a
feature shared by p53 as well [10]. Structurally, the p63 protein
is organized similar to p53 and p73 and consists of an N-termi-
nal activation domain, DNA-binding domain in the middle
and an oligomerization domain towards the C-terminus. As
expected, the highest homology between the p53 family mem-
bers is found in the DNA-binding domain. However, an
approximately 60% homology within the DNA-binding do-
main between these proteins is relatively modest compared to
other families of transcription factors such as AP-2 which
share up to 90% homology [1,11].
Transcriptionally active forms of p63 are likely to regulate
target gene expression by sequence-speciﬁc recognition of con-
trol response elements present in promoters and enhancers. Be-
cause both p53 and p63 contain similar DNA-binding
domains, it has been thought that the p63-response elements
are likely to be similar to that of the canonical p53 response
element. Indeed, several studies have shown that p63 can bind
to p53-response elements and activate transcription of p53-
inducible genes such as MDM2, p21, Bax and 14-3-3r [4].
However, increasingly it is becoming clear that unique p63 tar-
get genes exist, as would be expected from the fact that the
in vivo function of p63 is strikingly diﬀerent from p53.
One possible mechanism by which p63 can regulate unique
target genes is by preferentially binding to and activating dis-
tinct response elements. In this case, the selectivity of p63 tran-
scription factor for a speciﬁc promoter and/or enhancer will
depend to a large extent on the nature of the DNA-binding
site. However, to this date the nature of such p63-binding sites
has not been experimentally determined. Here we have
performed systematic evolution of ligands by exponential
enrichment (SELEX) experiments to decipher the optimum
DNA-binding sequence of p63. Our studies show that opti-
mum DNA-binding by p63 requires a CA(T)TG core and an
AT-rich 5 0 and 3 0 ﬂanking sequence. Interestingly, a systematic
biochemical analysis of the DNA consensus sequence by directblished by Elsevier B.V. All rights reserved.
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requires not only the speciﬁc core sequence, but that the ﬂank-
ing sequences also inﬂuence the aﬃnity of the protein to DNA.
This binding pattern is similar for both recombinant and na-
tive p63 and is distinct from that of p53 suggesting that
in vivo p63 may indeed bind to unique DNA sequences. The
wide range of DNA-binding aﬃnity of p63 may play an impor-
tant role in mediating its eﬀect on target gene expression.2. Materials and methods
2.1. Systematic evolution of ligands by exponential enrichment
(SELEX)
A 80-bp oligonucleotide was synthesized (IDT Technologies), which
contained 35-base random nucleotides ﬂanked by sequences comple-
mentary to primers A and B for cloning purposes. The sequences of
these three oligonucleotides are as follows: 80-base oligonucleotide,
5 0-GGATCCCTGCCTTCACCGAAGC (N)35 TTGGGGACTATG-
AATTCCTGAGG-3 0; primer A, 5 0-GGATCCCTGCCTTCACCGA-
AG-3 0; primer B, 5 0-CCTCAGGAATTCATAGTCCCC-3 0. A random
sequence library of double-stranded radiolabeled oligonucleotides was
prepared by annealing the 80-base oligonucleotide to 5-fold molar
excess of primer B followed by extension with Klenow.
The labeling reaction mixture contained 50 mM Tris–HCl (pH 7.5),
10 mMMgCl2, 100 lM each of dATP, dGTP and dTTP and was incu-
bated with 5 U of the Klenow enzyme at 37 C for 1 h in the presence
of [a-32P] dCTP. The radiolabeled probes were puriﬁed by using G-50
Nick columns (Amersham). Binding reactions were performed by add-
ing 100 ng of recombinant His-tagged DNp63 protein to DNA binding
buﬀer, DBB (5% glycerol, 10 mM HEPES, pH 7.9, 75 mM KCl, 1 mM
DTT, 2.5 mM MgCl2, 1 mM EDTA) containing 0.1 lg of poly
(dA Æ dT) poly(dA Æ dT) and 5 lg of bovine serum albumin. After incu-
bation at room temperature for 30 min, the protein–DNA complexes
were resolved by electrophoresis through a non-denaturing 5% poly-
acrylamide gel in 1· Tris–borate–EDTA (TBE) buﬀer at 100 V for
3 h. The complexes speciﬁcally formed in the presence of p63 proteins
were detected by autoradiography, excised from gels, and eluted over-
night at 65 C in DNA-elution buﬀer containing 0.3 M NaCl, 1 mM
EDTA, and 0.1% SDS. The eluted DNA was extracted once with phe-
nol–chloroform, and then precipitated with ethanol. Primers A and B
were used to PCR amplify the puriﬁed DNA in the presence of [a-32P]
dCTP. Ampliﬁcation was carried out by 20 cycles of denaturation at
94 C for 20 s, annealing at 49 C for 20 s, and extension at 72 C
for 30 s. The ampliﬁed DNA was puriﬁed using G-50 Nick columns,
and used in subsequent EMSA experiments. After four cycles of SE-
LEX, the ﬁnal ampliﬁed DNA was directly cloned using pCR2.1-Topo
TA Cloning kit (Invitrogen). Nucleotide sequences of 98 independent
clones were determined. The degenerate portion of the sequences
was compiled and analyzed for shared sequence patterns by visual
inspection and with matrix-based pattern and motif discovery pro-
grams such as MEME and CONSENSUS.
2.2. Plasmid constructions
The cDNAs corresponding to mouse DNp63a and DNp63c were
cloned into the BamHI and HindIII restriction enzyme sites of the
pCOLD vector (Takara). The cDNAs were obtained by searching the
expressed sequence tag (EST) database andweremodiﬁed by PCR strat-
egy for creating in-frame fusionwith theHis-tag. A plasmid for bacterial
expression of His-tagged p53 protein was a gift fromDr. Hua Lu. DNA
sequencing of all the constructs was performed to ensure proper reading
frame and the absence of any mistakes during PCR ampliﬁcation.
2.3. Expression and puriﬁcation of His-tagged proteins
The production and puriﬁcation of the His-tagged p53 and p63 pro-
teins from bacteria were performed according to the standard proto-
cols. Brieﬂy, cells were centrifuged, and the pellets were resuspended
in a buﬀer containing 50 mM Tris–Cl (pH 8.5), 100 mM NaCl, 1 mg/
ml lysozyme, 1 mM PMSF, 1% sarcosyl, and 1% Triton-X-100. The
cells were lysed by sonication followed by centrifugation of the lysate
at 8500 · g for 30 min. The supernatant was mixed with Ni-charged
His-Bind resin (Novagen) and the mixture was agitated for 30 min atroom temperature. The mixture was then centrifuged at 400 · g for
1 min and the supernatant was discarded. The His-bind resin was
washed thoroughly ﬁrst with binding buﬀer (0.5 M NaCl, 20 mM
Tris–HCl, 5 mM imidizole, pH 7.9) followed by wash buﬀer (0.5 M
NaCl, 60 mM imidizole and 20 mM Tris–HCl, pH 7.9). The recombi-
nant proteins were eluted in a buﬀer containing 1 M imidazole, 0.5 M
NaCl, and 20 mM Tris–HCl, pH 7.9. The quality and quantity of the
proteins were veriﬁed by SDS–PAGE followed by Coomassie brilliant
blue staining. Western blots were performed to address the anti-p53
and anti-p63 antibodies speciﬁcity.2.4. Electrophoretic mobility shift assays with His-p63, His-p53 and
keratinocyte nuclear extracts
Electrophoretic mobility shift assays (EMSAs) were performed with
either 100–300 ng of recombinant proteins or 5 lg of nuclear extracts
and end-labeled double-stranded oligonucleotides. Complementary
oligonucleotides were synthesized (IDT Technologies), annealed, and
2 pmole of double-stranded oligonucleotides were used for radioactive
labeling with [a-32P] dCTP by Klenow enzyme. The labeled probes
were puriﬁed by using G-50 Nick columns. Binding reactions were per-
formed at room temperature for 30 min in 20 ll of DBB. 0.1–0.5 lg of
poly (dA Æ dT) poly(dA Æ dT) was added to each reaction as a nonspe-
ciﬁc DNA competitor. Competition assays were performed by incubat-
ing recombinant proteins with 20-, 200-, or 400-fold excess unlabeled
oligonucleotides for 20 min before addition of radiolabeled probe.
The protein–DNA complexes were resolved by gel electrophoresis on
4% non-denaturing polyacrylamide gels in 1· TBE buﬀer at room tem-
perature. After electrophoresis, the gels were dried and visualized by
autoradiography. Anti-p63 and anti-Sp1 antibodies used for super-
shift experiments have been previously described [12]. Anti-p53 anti-
bodies were obtained from Santa Cruz (DO-1, sc-126).
2.5. Cell culture and preparation of nuclear extracts
HaCaT cells were grown in Dulbecco’s modiﬁed eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and
100 U/ml penicillin and 100 lg/ml streptomycin. Mouse keratinocytes
(MK) were grown in a low Ca2+ medium comprised of a 3:1 mixture
of Ham’s F12 and DMEM supplemented with 15% chelated FBS. Nu-
clear extracts from HaCaT and MK cells were prepared by standard
methods as described before [12].3. Results and discussion
3.1. Selection of p63 consensus DNA-binding sequences
The p53 family of proteins operates as transcription factors,
that binds speciﬁc DNA sequences and this activity is mediated
by the conserved DNA-binding domain. The canonical p53-
responsive element has been well described and typically con-
sists of tandem repeats of the sequence, RRRCWWGYYY,
where R, purine, C, cytosine, W, adenine or thymidine, G,
guanine and Y, pyrimidine. This sequence is commonly re-
peated as two pairs, where each of the 10 bp palindromic se-
quences are arranged as inverted repeats with a spacer in
between consisting of nucleotides that vary from 0 to approx-
imately 14 bp. Not surprisingly, p63 proteins have been shown
to bind to p53 consensus DNA binding sites both in vitro and
in vivo. However, the modest sequence similarity in the DNA-
binding domain of p53 and p63, the presence of unique targets
for these proteins, and their divergent biological role suggest
that there may be unique DNA-binding sequence requirements
for p63. As a ﬁrst step towards understanding these DNA se-
quence requirements for p63, we performed the selection of
p63 binding sequences in vitro using the SELEX method
[13]. For this purpose, we generated a radioactively labeled
pool of double-stranded oligonucleotides containing 35 bp of
random sequences in the center ﬂanked by primer sequences.
This DNA pool was incubated with recombinant His-DNp63a
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tive gel by EMSA. The p63-bound DNA was subsequently
recovered from the gel and subjected to 15–20 cycles of PCR
ampliﬁcation. With each round of such selection, an enrich-
ment of speciﬁc binding sites was obtained as observed by an
increased eﬃciency of p63–DNA complex formation (data
not shown). After ﬁve such rounds of selection, the ﬁnal
PCR products were cloned into pCR2.1Topo vector and 98
independent clones were sequenced.
3.2. Alignment of the selected p63 consensus DNA-binding
sequences
The sequences were analyzed by visual inspection as well as
aligned by using motif search programs such as CONSENSUSFig. 1. Identiﬁcation of p63 consensus binding site derived by SELEX. (A)
program CONSENSUS. Shown is the alignment of sequences by the position
CNRG. The consensus sequence is represented graphically as a sequence logo
98 independent clones derived from SELEX. The residues are based on the co
guanine as ‘‘7’’. For each position, the frequency of each nucleotide is indicat
consensus DNA-binding sequence: any nucleotide that is preferred over 50%
degenerate symbol representing the two nucleotides that are the most preferand MEME [14,15]. Speciﬁcally, we searched for potential
p53-like DNA-binding sequences, consisting of the CWWG
core. Of the 98 numbers of sequences that were examined, a
majority of them had varying degrees of match with the con-
sensus p53–DNA binding sequence. We have categorized these
sites into ﬁve groups based on the nature of the 4 bp core se-
quence CNNG. The most common core consisted of CATG
sequence, whereas other cores containing CGTG, CTTG and
CCTG were present in fewer numbers. Another group of 16 se-
quences were grouped separately, consisting of CNRG (where
R = A/G). The alignment of the p63-binding sequences is
shown and the consensus motif depicting the nucleotide distri-
bution that we obtained based on the aligned sequences is rep-
resented graphically as a sequence logo (Fig. 1A). For the sakeAlignment of the individual sequences generated by the motif search
of one of ﬁve common core sequences: CATG, CTTG, CCTG, CGTG,
on the bottom. (B) p63 binding site preference based on the sequence of
re sequence with the core cytosine designated as position ‘‘4’’ and core
ed as a percentage. The following criteria was used to illustrate the p63
is shown, if no nucleotide is preferred for more than 50%, then a double
red are shown.
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with the core cytosine being designated as position ‘‘4’’ and
core guanine as ‘‘7’’. What is clearly evident from these data
is the fact that while there is clearly a preference for C at posi-
tion 4, T for position 6 and G for position 7, the rest of the
positions exhibit less stringent preference for a single nucleo-
tide. Nevertheless, analysis of the sequences suggests that while
on the 5 0 end of the core sequence there is a preference for an A
nucleotide, on the 3 0 end of the core, there is a signiﬁcant
preference for T. Taken together, our experiments deﬁne the
optimal p63 DNA-binding consensus motif as (T/A)A(T)A-
CA(T)TGT(T/A)T consisting of a CA(T)TG core and AT-rich
5 0 and 3 0 ﬂanking sequences (Fig. 1B). Interestingly, none of
the sequences contained more than one copy of the consensus
site, which may be because of the limitation of the length of the
random sequences present within the synthetic oligonucleotide.
Alternately, it is possible that p63 may not have a particular
preference for tandem repeat sequences for optimum DNA
binding.
3.3. Analysis of selected p63 binding sequences by EMSA
The fact that the p63 consensus site consisted of a CA(T)TG
core sequence and a preference for A/T rich ﬂanking se-
quences, prompted us to examine experimentally the sequence
requirements in more detail. Speciﬁcally, we examined the
aﬃnity of p63 to the various core sequences and the role of
the 5 0 and 3 0 ﬂanking sequences. To facilitate these studies,
we divided the compiled sequences into four groups, each
group representing four diﬀerent core sequences (Table 1).
Thus, Group 1 consists of the core sequence CATG, Group
2 consisted of core sequence CTTG, Group 3 consisted of core
sequence CCTG, and Group 4 consisted of core sequence
CGTG. Within each group we chose four representative se-
quences, one that matches perfectly with the p63-consensus se-
quence, one that contains the core and a perfect match only on
the 5 0 ﬂanking sequence, one that contains the core and a per-
fect match only on the 3 0 ﬂanking sequence and a fourth that
only has a match with the core, while the ﬂanking sequences
are highly divergent from the consensus. In each case, the mis-Table 1
p63 binding sites divided into four groups based on core sequence (in bold)
Oligonucleotide Sequence
Group 1 1 GGA ATAAGTAT TAACATG
2 GGA ATAAGTAT ATACATG
3 GGA ATAAGTAT CGGCATG
4 GGA ATAAGTAT AGGCATG
Group 2 5 GGA ATAAGTAT TAACTTG
6 GGA ATAAGTAT AAACTTG
7 GGA ATAAGTAT GCCCTTG
8 GGA ATAAGTAT GAGCTTG
Group 3 9 GGA ATAAGTAT TAACCTG
10 GGA ATAAGTAT AAACCTG
11 GGA ATAAGTAT GTGCCTG
12 GGA ATAAGTAT GACCCTG
Group 4 13 GGA ATAAGTAT TAACGTG
14 GGA ATAAGTAT TAACGTG
15 GGA ATAAGTAT TGTCGTG
16 GGA ATAAGTAT CCCCGTG
Within each group 4 oligonucleotides represent sequences which were chosematch sequences of the 5 0 and 3 0 ﬂanking consist of nucleotides
which showed the lowest frequency at each position based on
the weight matrix. All these representative sequences were
picked from the clones that have been described in Fig. 1.
We next generated 16 oligonucleotide probes that were roughly
the same number of base pairs and contained these p63 recog-
nition sequences in the center. These probes were labeled to
approximately the same level of speciﬁc activity and tested
by EMSA with His-DNp63a. As shown in Fig. 2A, the EMSA
data revealed several interesting ﬁndings. Oligonucleotides 1–4
corresponding to Group 1 (core sequence CATG) bound to
p63 to a varying degree. While oligonucleotide 1 bound well
to p63, oligonucleotide 2 containing a mismatch in the 5 0 of
the core sequence did not bind well (lanes 1 and 2). However,
a mismatch on the 3 0 end did not aﬀect DNA-binding as illus-
trated by oligonucleotide 3 (lane 3). On the other hand, for
group 2 sequences (core sequence CTTG), oligonucleotide 5
with no mismatch on either side and oligonucleotide 6 with
mismatch on the 5 0 side were capable of binding to p63 quite
well (lanes 5 and 6). Both oligonucleotide 7 with mismatch
on the 3 0 side and oligonucleotide 8 with mismatch on both
sides bound to p63 very poorly (lanes 7 and 8). Oligonucleo-
tides 9–12 corresponding to group 3 containing CCTG core
tolerated deviations from the consensus sequence on either side
quite well, however showed no binding to p63 when both sides
were mismatched (lanes 9–12). Finally, group 4 sequences rep-
resenting the CGTG core sequences showed eﬃcient binding
to p63 only when the match to the consensus was on both sides
of the core (lanes 13–16). Thus for each core, several oligonu-
cleotides that deviated from the consensus sequences in the 5 0
end, 3 0 end or from both sides exhibited moderate or weak
binding. In addition, although an A or a T was the preferred
nucleotide for position 5 in the core, p63 could also tolerate
C and G as illustrated by the DNA-binding of group 3 and
4 oligonucleotides. Collectively, our data suggests that oligo-
nucleotides that more closely resemble the p63 consensus se-
quence show stronger aﬃnity for p63 and that not only the
core but also the ﬂanking sequences play an important role
in governing the binding of p63 to DNA.Binding aﬃnity Competes?
TTT AGAATAGG ++++ Yes
GCC AGAATAGG ++ Weakly
TTT AGAATAGG ++++ Yes
ATG AGAATAGG +++ Yes
TAT AGAATAGG ++++ Yes
CCC AGAATAGG ++++ Yes
TTA AGAATAGG +/ Weakly
ATT AGAATAGG + Yes
TAT AGAATAGG ++++ Yes
CCC AGAATAGG ++++ Yes
TTT AGAATAGG +++ Yes
ACC AGAATAGG  No
TAT AGAATAGG ++++ Yes
ACT AGAATAGG + Weakly
TTT AGAATAGG + No
CAC AGAATAGG  No
n based on match with ﬂanking sequence.
CATG CTTG CCTG CGTG
A
B
1
p63
 1     2      3     4     5     6      7     8     9    10    11   12    13   14  15   16
2 3 4 5 6
7 8 9 10 11 12
13 14 15 16
o
lig
o 
1
Fig. 2. EMSA reveals the binding speciﬁcity of p63 to 16 diﬀerent oligonucleotides with diﬀerent degrees of match with the consensus sequence.
Numbers on the bottom of each lane indicate the speciﬁc oligonucleotides (listed in Table 1) used in this experiment. (A) EMSA showing DNA
binding of DNp63a to four groups of selected oligonucleotides. (B) Competition for p63 binding by four groups of the selected binding sites.
Oligonucleotide 1 was radiolabeled and 20-, 200-, and 400-fold excess amount of the 16 diﬀerent unlabeled oligonucleotides as indicated above each
lane were added to the binding reaction for competition analysis. Only the DNA–protein complexes are shown.
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oligonucleotides to DNp63a, we also conﬁrmed the aﬃnity
of these sequences to DNp63a by performing competition
experiments (Fig. 2B). For this purpose, the oligonucleotides
corresponding to sequence 1 were radiolabeled and 20-, 200-
and 400-fold excess amount of the 16 diﬀerent cold oligonu-
cleotides was used to compete the binding of DNp63a. The
competition experiments validated the data obtained from di-
rect binding, since the degree of competition was as expected
from the direct binding studies from Fig. 2A, with strong
competition by sequences that matched with the p63 consen-
sus sequences and progressively weaker competition with se-
quences that diverged from p63 consensus sequences. Theserelative binding aﬃnities of the diﬀerent sequences are sum-
marized in Table 1.
Since the p63 gene encodes for a variety of isoforms, one pos-
sibility is that p63 isoforms may diﬀerentially bind DNA. In-
deed, some recent studies suggest that this might be the case
as is evident for one recently described p63 target gene,
GPX3, which contains a p63-responsive element that is specif-
ically responsive to p63c and not p63a [16]. To test for diﬀerent
DNA-binding properties of p63 isoforms, we generated His-
DNp63c and repeated the EMSA studies with previously de-
scribed 16 diﬀerent oligonucleotide probes that represented
various degrees of match with the p63 consensus sequence.
The pattern of DNA-binding for DNp63cwas indistinguishable
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least in vitro, two major isoforms of p63 show no signiﬁcant
diﬀerence in DNA binding as expected from the fact that they
both share an identical DNA-binding domain. However,
in vivo it is possible that additional events such as post-transla-
tional modiﬁcations and protein–protein interactions may im-
part some degree of speciﬁcity to various p63 isoforms.
3.4. Comparison of the DNA-binding speciﬁcity of p63 with
endogenous p63
It is possible that the binding activity of the recombinant
p63 proteins that were puriﬁed from bacteria may not reﬂect
the binding properties of native protein. This could be due to
many reasons such as improper folding, non-physiological
amounts of the protein and lack of potential post-transla-
tional modiﬁcations. To test if the binding properties that
we observe with His-p63 are similar to that of endogenous
p63, we utilized two diﬀerent cell lines, HaCaT and MK. Ha-
CaT keratinocytes contain mutant p53, high levels of p63 and
exhibit complex interactions between p53 and p63 [17]. Since
recombinant proteins used in this study were generated with
mouse p63 cDNAs, a mouse keratinocyte cell line, MK was
utilized to account for any potential species diﬀerence. Nucle-
ar extracts from both HaCaT and MK cells were tested with
the 16 oligonucleotides containing the various core and ﬂank-
ing sequences as well as an oligonucleotide containing the
p53-consensus sequence (Fig. 3A and B). Incubation of the
p53-consensus oligonucleotide with nuclear extract resulted
in a slow-moving complex, which could be speciﬁcally super-
shifted with antibodies against p63 but not with antibodies
against p53 or Sp1. This conﬁrmed that this complex consists
of endogenous p63. The antibodies against p53 and p63 were
speciﬁc and did not cross react (Supplementary Fig. 1). Inter-
estingly, native p63 from both human and mouse bound to
the 16 oligonucleotides in a fashion very similar to the recom-
binant protein. Each of the DNA–protein complexes was
formed by p63 as evident by the migration pattern and the
fact that each complex reacted with antibodies against p63
(data not shown). These data indicate that the consensus se-
quence information obtained from our in vitro studies may
be useful in assessing the DNA-binding aﬃnity of the endog-
enous p63 proteins.Fig. 3. DNA-binding speciﬁcity of endogenous p63 is similar to that of reco
were tested with the 16 oligonucleotides as well as an oligonucleotide co
oligonucleotides used in this experiment and the sequences can be found
GGTTACAGAACATGTCTAAGCATGCTGGGG-3 0. While antibodies dir
a super-shift of the complex, indicating that the complex is p63. Only the D3.5. Comparison of the DNA-binding speciﬁcity of p63 with p53
As shown by several studies the typical p53-response element
is a palindrome sequence (RRRCWWGYYY) [18,19]. Interest-
ingly, p53 binds preferably to the CATG core sequence, sug-
gesting that p53 binds more eﬃciently to structurally perfect
bidirectional palindromes. In contrast, a recent study has shown
that p63 has much higher speciﬁcity for the CGTG (non-palin-
dromic) core sequence than p53 as suggested by reporter analy-
sis of mutated response elements and by DNA–protein binding
assays [20]. However, our in vitro data seems to indicate that the
preferred binding site for p63 binding sites contains the CATG
core since it is the most common core motif isolated from the
random library of sequences and it tolerates mismatches on
the 5 0 and 3 0 side very well. The diﬀerence between these results
could be because of the fact that the previous studies were per-
formed with TAp63 proteins. Nevertheless, what is evident
from these studies is that there is a great deal of heterogeneity
of DNA-binding sites for p53 and p63 proteins, which may re-
ﬂect a diﬀerence in their DNA-binding properties. To analyze
this further experimentally, we compared the DNA-binding
properties of p53 and p63 by performing EMSA with recombi-
nant proteins. We utilized the 16 oligonucleotides that repre-
sented the four diﬀerent groups of p63 binding sites that were
derived from the SELEX experiments described before. Inter-
estingly, His-p53 showed diﬀerent degrees of DNA-binding
activity with the 16 oligonucleotides, when compared to p63
(Fig. 4). Indeed, p53 DNA-binding was more promiscuous,
since it tolerated a wide variety of mismatches compared to
p63. The most striking diﬀerence was observed with oligonucle-
otides 7, 12 and 16, which showed signiﬁcantly better binding to
p53 than to p63. Taken together, our data suggest that although
these diﬀerences in aﬃnity for speciﬁcDNA-binding sites of p63
and p53 are subtle, they may have important implications for
target gene speciﬁcity in vivo.
To date only about 15 genes have been shown to contain
DNA-responsive elements that bind to p63 protein and are
transcriptionally regulated by it. In light of our newly derived
p63 consensus sequence, we examined these binding sites of
p63 as described in the literature to see if they bear resem-
blance to the consensus. Interestingly many of them matched
our derived consensus sequence very well with very few mis-
matches (see supplementary Table 1). For some of the targetmbinant protein. Nuclear extracts from HaCaT cells (A) and MK (B)
ntaining the p53-consensus sequence. Numbers refer to the speciﬁc
in Table 1. The p53-consensus sequence used for the EMSA is 5 0-
ected against p53 and Sp1 had no eﬀect, anti-p63 antibodies resulted in
NA–protein complexes are shown.
CATG CTTG CCTG CGTG
p63
p53
   1      2      3      4       5      6      7      8      9     10    11    12    13    14    15   16
                    *              *              *                      *       *      *                             *
Fig. 4. Comparison of the DNA-binding speciﬁcity of p63 with p53 by EMSA. His-p63 and His-p53 proteins were each tested with the 16
oligonucleotides to compare the binding activities of the two proteins. Numbers on the bottom of each lane refer to the speciﬁc oligonucleotide used
in this experiment. Only the DNA–protein complexes are shown. The asterisks indicate those lanes, which show signiﬁcant diﬀerence in the binding
activity between p63 and p53.
4550 K. Ortt, S. Sinha / FEBS Letters 580 (2006) 4544–4550genes, there were many p53-like binding sites that were de-
scribed, but these were not analyzed for p63 binding. Our
new consensus could prove to be useful in detecting in silico
the potential p63 binding sites that are present in regulatory
regions for these genes as well as in future targets.
Similar to p53, the degenerate nature of the p63 DNA-bind-
ing sequence might be important in providing diversity and
ﬂexibility in transcriptional regulatory controls. However, this
variability or degeneracy also makes it diﬃcult to identify
bona ﬁde p63 binding sites in target genes. Our analysis sug-
gests that although DNA-binding by p63 is ﬂexible, there ex-
ists a distinct sequence signature that results in stronger
binding speciﬁcally of p63. Importantly, this sequence signa-
ture consists of not only the core region but also ﬂanking se-
quences surrounding the core. The availability of the p63
consensus sequence is a ﬁrst step towards validating the
in vivo targets of p63 and sorting out high aﬃnity sites from
those that are potentially weak.
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